Literature DB >> 19348913

Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.

Makoto Miyara1, Kajsa Wing, Shimon Sakaguchi.   

Abstract

Forkhead box protein 3-positive regulatory T (Treg) cells are indispensable for the maintenance of self-tolerance and immune homeostasis. They can also be exploited for the treatment of immunologic diseases, including autoimmune diseases and allergy, by way of activating and expanding antigen-specific Treg cells in vivo. Cell therapy with in vitro activated and expanded Treg cells can be another therapeutic modality. The feasibility of such Treg cell-based therapeutic strategies is discussed based on recent advances in our understanding of the molecular and cellular basis of Treg cell development and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19348913     DOI: 10.1016/j.jaci.2009.03.001

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  32 in total

1.  Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Stephan Lang; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2011-04-13       Impact factor: 2.303

2.  Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells.

Authors:  Hye-Sook Kwon; Hyung W Lim; Jessica Wu; Martina Schnölzer; Eric Verdin; Melanie Ott
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

3.  Forkhead box P3+ T cells express interleukin-17 in nasal mucosa of patients with both allergic rhinitis and polyposis.

Authors:  T Liu; C-H Song; A-M Liu; C Xie; F Zhao; X Chen; L Cheng; P-C Yang
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

4.  Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection.

Authors:  Steven Kho; Jutta Marfurt; Rintis Noviyanti; Andreas Kusuma; Kim A Piera; Faustina H Burdam; Enny Kenangalem; Daniel A Lampah; Christian R Engwerda; Jeanne R Poespoprodjo; Ric N Price; Nicholas M Anstey; Gabriela Minigo; Tonia Woodberry
Journal:  Infect Immun       Date:  2015-06-01       Impact factor: 3.441

Review 5.  The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.

Authors:  A Mohr; M Atif; R Balderas; G Gorochov; M Miyara
Journal:  Clin Exp Immunol       Date:  2019-03-24       Impact factor: 4.330

6.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

7.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

Review 8.  Is the CCR5 Δ 32 mutation associated with immune system-related diseases?

Authors:  Khodayar Ghorban; Maryam Dadmanesh; Gholamhossein Hassanshahi; Mohammad Momeni; Mohammad Zare-Bidaki; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

9.  1,25-dihydroxyvitamin D3 enhances the ability of transferred CD4+ CD25+ cells to modulate T helper type 2-driven asthmatic responses.

Authors:  Shelley Gorman; Melinda A Judge; Jennifer T Burchell; Debra J Turner; Prue H Hart
Journal:  Immunology       Date:  2010-01-06       Impact factor: 7.397

Review 10.  Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases?

Authors:  Mojgan Noroozi Karimabad; Mohammad Kazemi Arababadi; Elham Hakimizadeh; Hassan Yousefi Daredori; Mahmood Nazari; Gholamhossein Hassanshahi; Derek Kennedy
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.